Literature DB >> 21436957

Pediatric ethics guidelines for hereditary medullary thyroid cancer.

M Sara Rosenthal1, Douglas S Diekema.   

Abstract

Hereditary medullary thyroid cancer is an aggressive cancer for which there is no standard effective systemic therapy, but which can be prevented through genetic screening and prophylactic thyroidectomy. Although this cancer accounts for roughly 17% of all pediatric thyroid cancers, a significant percentage of affected families do not "accept" screening, while many gene carriers delay or refuse prophylactic thyroid surgery for their children. Current genetic screening practices in medullary thyroid cancer are inadequate; more than 50% of index patients with hereditary medullary thyroid cancer present with a thyroid mass; up to 75% have distant metastasis. These proposed pediatric ethics guidelines focus on two ethical issues that affect at-risk children: (1) how do we identify at-risk children whose RET-positive relative refuses to disclose that they carry the mutation? (2) How do we protect RET-positive children whose parents refuse prophylactic thyroidectomy?

Entities:  

Year:  2011        PMID: 21436957      PMCID: PMC3198744          DOI: 10.1155/2011/847603

Source DB:  PubMed          Journal:  Int J Pediatr Endocrinol        ISSN: 1687-9848


  65 in total

1.  Familial medullary thyroid carcinoma: presymptomatic diagnosis and management in children.

Authors:  R A Heptulla; R P Schwartz; A E Bale; S Flynn; M Genel
Journal:  J Pediatr       Date:  1999-09       Impact factor: 4.406

2.  Cost analysis of DNA-based testing in a large Canadian family with multiple endocrine neoplasia type 2.

Authors:  D M Gilchrist; D W Morrish; P J Bridge; J L Brown
Journal:  Clin Genet       Date:  2004-10       Impact factor: 4.438

3.  Risk and penetrance of primary hyperparathyroidism in multiple endocrine neoplasia type 2A families with mutations at codon 634 of the RET proto-oncogene. Groupe D'etude des Tumeurs à Calcitonine.

Authors:  I Schuffenecker; M Virally-Monod; R Brohet; D Goldgar; B Conte-Devolx; L Leclerc; O Chabre; A Boneu; J Caron; C Houdent; E Modigliani; V Rohmer; M Schlumberger; C Eng; P J Guillausseau; G M Lenoir
Journal:  J Clin Endocrinol Metab       Date:  1998-02       Impact factor: 5.958

Review 4.  Review: Should patients with apparently sporadic pheochromocytomas or paragangliomas be screened for hereditary syndromes?

Authors:  Camilo Jiménez; Gilbert Cote; Andrew Arnold; Robert F Gagel
Journal:  J Clin Endocrinol Metab       Date:  2006-05-30       Impact factor: 5.958

Review 5.  Medullary thyroid carcinoma: role of genetic testing and calcitonin measurement.

Authors:  C J Lips; J W Höppener; J H Thijssen
Journal:  Ann Clin Biochem       Date:  2001-05       Impact factor: 2.057

6.  Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A.

Authors:  Michael A Skinner; Jeffrey A Moley; William G Dilley; Kouros Owzar; Mary K Debenedetti; Samuel A Wells
Journal:  N Engl J Med       Date:  2005-09-15       Impact factor: 91.245

Review 7.  RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors.

Authors:  Maria A Kouvaraki; Suzanne E Shapiro; Nancy D Perrier; Gilbert J Cote; Robert F Gagel; Ana O Hoff; Steven I Sherman; Jeffrey E Lee; Douglas B Evans
Journal:  Thyroid       Date:  2005-06       Impact factor: 6.568

Review 8.  Bioethics for clinicians: 3. Capacity.

Authors:  E Etchells; G Sharpe; C Elliott; P A Singer
Journal:  CMAJ       Date:  1996-09-15       Impact factor: 8.262

Review 9.  Genetic testing in multiple endocrine neoplasia and related syndromes.

Authors:  A Calender
Journal:  Forum (Genova)       Date:  1998 Apr-Jun

10.  Phenotypic expression of a family with multiple endocrine neoplasia type 2A due to a RET mutation at codon 618.

Authors:  S Lindskog; O Nilsson; S Jansson; B Nilsson; A-C Illerskog; L Ysander; H Ahlman; L-E Tisell
Journal:  Br J Surg       Date:  2004-06       Impact factor: 6.939

View more
  4 in total

Review 1.  Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.

Authors:  Samuel A Wells; Sylvia L Asa; Henning Dralle; Rossella Elisei; Douglas B Evans; Robert F Gagel; Nancy Lee; Andreas Machens; Jeffrey F Moley; Furio Pacini; Friedhelm Raue; Karin Frank-Raue; Bruce Robinson; M Sara Rosenthal; Massimo Santoro; Martin Schlumberger; Manisha Shah; Steven G Waguespack
Journal:  Thyroid       Date:  2015-06       Impact factor: 6.568

Review 2.  Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update.

Authors:  Samuel A Wells; Furio Pacini; Bruce G Robinson; Massimo Santoro
Journal:  J Clin Endocrinol Metab       Date:  2013-06-06       Impact factor: 5.958

3.  Crude annual incidence rate of medullary thyroid cancer and RET mutation frequency.

Authors:  Sara Milićević; Damijan Bergant; Tina Žagar; Barbara Perić
Journal:  Croat Med J       Date:  2021-04-30       Impact factor: 1.351

4.  Nuclear Medicine in Thyroid Diseases in Pediatric and Adolescent Patients.

Authors:  Bilge Volkan-Salancı; Pınar Özgen Kıratlı
Journal:  Mol Imaging Radionucl Ther       Date:  2015-06-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.